Based on the Kazia Therapeutics Ltd ADR stock forecast from 1 analysts, the average analyst target price for Kazia Therapeutics Ltd ADR is USD 3.00 over the next 12 months. Kazia Therapeutics Ltd ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Kazia Therapeutics Ltd ADR is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Kazia Therapeutics Ltd ADR’s stock price was USD 0.79. Kazia Therapeutics Ltd ADR’s stock price has changed by +11.17% over the past week, -20.69% over the past month and -94.86% over the last year.
No recent analyst target price found for Kazia Therapeutics Ltd ADR
No recent average analyst rating found for Kazia Therapeutics Ltd ADR
Company Overview Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. Read Less
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target ...Read More
Frequently Asked Questions About Kazia Therapeutics Ltd ADR (KZIA) Stock
Based on ratings from 1 analysts Kazia Therapeutics Ltd ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on KZIA's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for KZIA is USD 3.00 over the next 12 months. The maximum analyst target price is USD 3 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on KZIA's stock to indicate if its overvalued.
The last closing price of KZIA's stock was USD 0.79.
The most recent market capitalization for KZIA is USD 4.30M.
Based on targets from 1 analysts, the average taret price for KZIA is projected at USD 3.00 over the next 12 months.
This means that KZIA's stock price may go up by +280.08% over the next 12 months.
We can't find any ETFs which contains Kazia Therapeutics Ltd ADR's stock.
As per our most recent records Kazia Therapeutics Ltd ADR has 0 Employees.
Kazia Therapeutics Ltd ADR's registered address is Three International Towers, Sydney, NSW, Australia, 2000.
You can get more information about it from Kazia Therapeutics Ltd ADR's website at https://www.kaziatherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Kazia Therapeutics Ltd ADR (KZIA) Stock
Based on ratings from 1 analysts Kazia Therapeutics Ltd ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on KZIA's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for KZIA is USD 3.00 over the next 12 months. The maximum analyst target price is USD 3 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on KZIA's stock to indicate if its overvalued.
The last closing price of KZIA's stock was USD 0.79.
The most recent market capitalization for KZIA is USD 4.30M.
Based on targets from 1 analysts, the average taret price for KZIA is projected at USD 3.00 over the next 12 months.
This means that KZIA's stock price may go up by +280.08% over the next 12 months.
We can't find any ETFs which contains Kazia Therapeutics Ltd ADR's stock.
As per our most recent records Kazia Therapeutics Ltd ADR has 0 Employees.
Kazia Therapeutics Ltd ADR's registered address is Three International Towers, Sydney, NSW, Australia, 2000.
You can get more information about it from Kazia Therapeutics Ltd ADR's website at https://www.kaziatherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for KZIA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
